These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34399555)

  • 1. [Correlation between clinical manifestation, prognosis and antibody in anti-muscle-specific tyrosine kinase antibody positive myasthenia gravis].
    Tan Y; Zhu L; Huang YY; Shi JY; Li J; Li K; Guan YZ; Cui LY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(31):2433-2437. PubMed ID: 34399555
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study.
    Zhao S; Zhang K; Ren K; Lu J; Ma C; Zhao C; Li Z; Guo J
    BMC Neurol; 2021 Nov; 21(1):428. PubMed ID: 34732168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics and outcomes of myasthenia gravis patients with double positive antibodies against acetylcholine receptor and muscle-specific tyrosine kinase].
    Lu YR; Yu L; Ma Q; Chen P; Qiu L; Ou CY; Lin ZZ; Liu WB
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):942-947. PubMed ID: 35385966
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of rituximab on prognosis in myasthenia gravis: A single-center experience from Turkey].
    Göl MF; Kara F; Boz M; Mutlu A; Karakullukçu S; Boz C
    Ideggyogy Sz; 2022 Sep; 75(9-10):351-359. PubMed ID: 36218113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Distribution characteristics and correlation analysis of antibody detection value in myasthenia gravis].
    Liu YL; Zheng YM; Luo JJ; Zhang W; Gao F; Yuan Y; Hao HJ
    Zhonghua Yi Xue Za Zhi; 2019 Nov; 99(41):3221-3226. PubMed ID: 31694116
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
    Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
    Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status.
    Usmani A; Kwan L; Wahib-Khalil D; Trivedi J; Nations S; Sarode R
    J Clin Apher; 2019 Aug; 34(4):416-422. PubMed ID: 30779438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Childhood-onset anti-MuSK antibody positive myasthenia gravis demonstrates a distinct clinical course.
    Takahashi Y; Sugiyama M; Ueda Y; Itoh T; Yagyu K; Shiraishi H; Ukeba-Terashita Y; Nakanishi M; Nagashima T; Imai T; Motomura M; Saitoh S
    Brain Dev; 2012 Oct; 34(9):784-6. PubMed ID: 22277190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
    Wang L; Wang S; Yang H; Han J; Zhao X; Han S; Zhang Y; Lv J; Zhang J; Li M; Ji Y; Zhou S; He X; Fang H; Yang J; Zhang Y; Zhang Q; Gao P; Gao F
    Brain Behav; 2021 Jul; 11(7):e02203. PubMed ID: 34075720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.
    Clifford KM; Hobson-Webb LD; Benatar M; Burns TM; Barnett C; Silvestri NJ; Howard JF; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; Laboy SM; Fellman MA; Howard DB; Kolb NA; Greene SM; Pasnoor M; Dimachkie MM; Barohn RJ; Hehir MK
    Muscle Nerve; 2019 Apr; 59(4):404-410. PubMed ID: 30575980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Titer of anti-muscle-specific receptor tyrosine kinase (MuSK) antibody correlated with symptomatic improvement in response to corticosteroid therapy in a patient with anti-MuSK antibody-positive myasthenia gravis: a case report].
    Nakahama Y; Kawajiri M; Ochi M; Kohara K; Ohta K; Miki T
    Rinsho Shinkeigaku; 2007 Jun; 47(6):356-8. PubMed ID: 17633110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse?
    Triplett JD; Hardy TA; Riminton DS; Chu SYK; Reddel SW
    Muscle Nerve; 2019 Sep; 60(3):307-311. PubMed ID: 31177576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MuSK-Ab positive myasthenia: not always grave.
    Zouvelou V; Stamboulis E; Skriapa L; Tzartos SJ
    J Neurol Sci; 2013 Aug; 331(1-2):150-1. PubMed ID: 23706725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome.
    Yildiz Celik S; Durmus H; Yilmaz V; Saruhan Direskeneli G; Gulsen Parman Y; Serdaroglu Oflazer P; Deymeer F
    Acta Neurol Belg; 2020 Feb; 120(1):133-140. PubMed ID: 31811563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance plasma exchange treatment for muscle specific kinase antibody positive myasthenia gravis patients.
    Yamada C; Teener JW; Davenport RD; Cooling L
    J Clin Apher; 2015 Oct; 30(5):314-9. PubMed ID: 25557356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis.
    Nikolic A; Djukic P; Basta I; Hajdukovic Lj; Stojanovic VR; Stevic Z; Nikolic D; Bozic V; Lavrnic S; Lavrnic D
    Clin Neurol Neurosurg; 2013 Apr; 115(4):432-7. PubMed ID: 22770539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and experimental features of MuSK antibody positive MG in Japan.
    Ohta K; Shigemoto K; Fujinami A; Maruyama N; Konishi T; Ohta M
    Eur J Neurol; 2007 Sep; 14(9):1029-34. PubMed ID: 17718696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review.
    Lu Y; Ran H; Yang W; Ma Q; Qiu L; Ou C; Chen P; Lin Z; Liu W
    Neuromuscul Disord; 2020 Jul; 30(7):534-538. PubMed ID: 32387283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.